Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Core Insights - Aprea Therapeutics, Inc. has entered into a securities purchase agreement to sell 2,623,023 shares of common stock and warrants to purchase an equal number of shares, raising approximately $3.1 million before expenses [2][3] Financing Details - The offering price for each share and accompanying warrant is set at $1.165, with warrants having an exercise price of $1.04 per share, exercisable immediately and expiring five years from the registration statement effectiveness date [2][3] - The gross proceeds from the offering are intended for general corporate purposes and research and development expenses, extending the company's cash runway into Q1 2027 [3] Company Overview - Aprea Therapeutics is focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells, with applications across various cancer types including ovarian, endometrial, colorectal, prostate, and breast cancers [7] - The company's lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications [8]